ArticleKidney international reports2026
Circulating Antinephrin Antibodies in Adult Chinese Patients With IgAN and Nephrotic-Range Proteinuria.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antinephrin Antibodies in IgAN: Toward a Phenotype-Driven, Personalized Approach.Kidney international reports · 2026Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Antinephrin autoantibodies are detectable in podocytopathies such as minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS); however, their prevalence and clinical relevance in IgA nephropathy (IgAN) with nephrotic-range proteinuria (NRP) and nephrotic syndrome (NS) are unclear. Methods: This single-center retrospective study enrolled 234 adults with biopsy-proven IgAN and NRP (≥ 3.5 g/d) from 2003 to 2020. Plasma antinephrin IgG and IgM were measured using enzyme-linked immunosorbent assay. Prespecified subgroups included NS ( Results: Overall antinephrin seropositivity was 8% (IgG: 6%, IgM: 2%). The seropositivity rate was 35% in patients with MCD versus 6% in those without. In patients with NS, seropositivity was 14%; rates were 35% with and 10% without MCD. Seropositive patients had heavier proteinuria (median: 8.1 vs. 4.9 g/d), lower serum albumin (21.9 ± 6.5 vs. 31.0 ± 7.2 g/l), fewer urinary red blood cells (RBCs), and similar estimated glomerular filtration rate (eGFR). Their biopsies showed milder chronic lesions (more M0/S0/T0). Seropositive patients more often received glucocorticoids and achieved higher complete remission (CR) rates (67% vs. 30% overall; 80% vs. 43% within NS) and fewer composite renal endpoints (0% vs. 28%). Multivariable analysis showed that antinephrin positivity was associated with a trend toward higher CR rates. Conclusion: Circulating antinephrin antibodies mark a podocytopathy-like phenotype in IgAN with MCD (MCD-IgAN) and define a distinct NS phenotype in patients with IgAN without overt podocytopathy. Targeted serologic testing could facilitate subgroup identification and guide tailored management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.